EP Patent

EP4417254A3 — Compressed macitentan compositions, methods and uses thereof

Assigned to Tecnimede Sociedade Tecnico Medicinal SA · Expires 2025-03-05 · 1y expired

What this patent protects

The present disclosure also relates to compressed compositions comprising a therapeutically effective amount of macitentan, a sugar alcohol diluent and a surfactant. It also relates to the process of obtaining said compressed compositions, oral pharmaceutical compositions compris…

USPTO Abstract

The present disclosure also relates to compressed compositions comprising a therapeutically effective amount of macitentan, a sugar alcohol diluent and a surfactant. It also relates to the process of obtaining said compressed compositions, oral pharmaceutical compositions comprising them, and their use in the treatment of pulmonary arterial hypertension.The present disclosure also relates to solid oral pharmaceutical compositions comprising a therapeutically effective amount of macitentan that simultaneously display improved stability properties and adequate dissolution profiles represents an unmet need in the field of pharmaceutical macitentan formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP4417254A3
Jurisdiction
EP
Classification
—
Expires
2025-03-05
Drug substance claim
No
Drug product claim
No
Assignee
Tecnimede Sociedade Tecnico Medicinal SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.